Atossa Therapeutics Inc’s filing revealed that its Director Remmel H. Lawrence acquired Company’s shares for reported $7000.0 on Mar 26 ’25. In the deal valued at $0.70 per share,10,000 shares were bought. As a result of this transaction, Remmel H. Lawrence now holds 10,257 shares worth roughly $6667.05.
Maxim Group initiated its Atossa Therapeutics Inc [ATOS] rating to a Buy in a research note published on January 26, 2018; the price target was $2.
Price Performance Review of ATOS
On Friday, Atossa Therapeutics Inc [NASDAQ:ATOS] saw its stock jump 9.56% to $0.65. Over the last five days, the stock has gained 7.49%. Atossa Therapeutics Inc shares have fallen nearly -31.56% since the year began. Nevertheless, the stocks have fallen -63.08% over the past one year. While a 52-week high of $1.84 was reached on 01/03/25, a 52-week low of $0.55 was recorded on 04/07/25. SMA at 50 days reached $0.7406, while 200 days put it at $1.1353.
Levels Of Support And Resistance For ATOS Stock
The 24-hour chart illustrates a support level at 0.6073, which if violated will result in even more drops to 0.5686. On the upside, there is a resistance level at 0.6672. A further resistance level may holdings at 0.6884. The Relative Strength Index (RSI) on the 14-day chart is 44.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0362, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.99%. Stochastics %K at 30.37% indicates the stock is a holding.
How much short interest is there in Atossa Therapeutics Inc?
A steep rise in short interest was recorded in Atossa Therapeutics Inc stocks on 2025-03-31, dropping by -0.77 million shares to a total of 8.1 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 8.86 million shares. There was a decline of -9.45%, which implies that there is a negative sentiment for the stock.
